Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05737303 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 11, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Start date changed from estimate of Feb 24, 2023 to Nov 27, 2023
    • Collaborators revised (10)
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
Trial Details
NCT Number NCT05737303
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Jiaxing Maternity and Child Health Care Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, Zhejiang University, School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Sun Yat-Sen University Cancer Center, Qilu Hospital of Shandong University, Ningbo No. 1 Hospital, Ningbo Women & Children's Hospital, Sir Run Run Shaw Hospital
Conditions
(from sponsor)		 Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV
Related terms Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Enrollment 538 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov